Stock listing
Oslo:ABS Arctic Bioscience AS Aksje
Home listing (Oslo) of Arctic Bioscience AS
Follow Arctic Bioscience AS into a list and get an email when it puts out news.
Share price · OSL:ABS
2.53 NOK -0.16 (-5.9%)
Close on Nov 20, 2026
- Day range
- 2.25 – 2.55 NOKNov 20, 2026
- Volume
- 14,453 sharesNov 20, 2026
- Market cap
- 68.20M NOKAt the close on Nov 20, 2026 · price × 26.96M shares outstanding
- 52-week range
- 2.05 – 3.90 NOKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 19,478 NOKMedian day 1,764 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Oslo:ABS · Home | 2.53 NOK | -0.16 (-5.9%) | 14,453 | 2.55 | 2.55 | 2.25 | 2.69 | Close on Nov 20, 2026 |
| Frankfurt:9TD | €0.209 EUR | -0.014 (-6.3%) | — | €0.209 | €0.209 | €0.209 | €0.223 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OSL:ABS · NOK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.53 | -0.16 | -5.9% | 2.55 | 2.55 | 2.25 | 14,453 | |
| 2.69 | 0.00 | 0.0% | 2.50 | 2.69 | 2.50 | 1,366 | |
| 2.69 | -0.07 | -2.5% | 2.50 | 2.69 | 2.50 | 940 | |
| 2.76 | +0.22 | +8.7% | 2.76 | 2.76 | 2.76 | 264 | |
| 2.54 | +0.09 | +3.7% | 2.54 | 2.54 | 2.54 | 100 | |
| 2.45 | +0.16 | +7.0% | 2.61 | 2.61 | 2.40 | 5,374 | |
| 2.29 | -0.21 | -8.4% | 2.20 | 2.49 | 2.10 | 64,968 | |
| 2.50 | -0.05 | -2.0% | 2.67 | 2.67 | 2.50 | 12,730 | |
| 2.55 | +0.16 | +6.7% | 2.20 | 2.55 | 2.20 | 800 | |
| 2.39 | -0.31 | -11.5% | 2.20 | 2.42 | 2.20 | 17,885 | |
| 2.70 | 0.00 | 0.0% | 2.70 | 2.70 | 2.70 | 30 | |
| 2.70 | +0.27 | +11.1% | 2.70 | 2.70 | 2.70 | 30 | |
| 2.43 | -0.06 | -2.4% | 2.20 | 2.43 | 2.20 | 200 | |
| 2.49 | +0.29 | +13.2% | 2.53 | 2.53 | 2.49 | 170 | |
| 2.20 | 0.00 | 0.0% | 2.10 | 2.28 | 2.10 | 1,801 | |
| 2.20 | -0.20 | -8.3% | 2.30 | 2.41 | 2.17 | 18,400 | |
| 2.40 | -0.17 | -6.6% | 2.33 | 2.49 | 2.05 | 7,278 | |
| 2.57 | -0.03 | -1.2% | 2.57 | 2.57 | 2.57 | 100 | |
| 2.60 | +0.24 | +10.2% | 2.60 | 2.60 | 2.60 | 1,000 | |
| 2.36 | +0.07 | +3.1% | 2.36 | 2.36 | 2.36 | 1,010 | |
| 2.29 | +0.19 | +9.0% | 2.20 | 2.36 | 2.20 | 1,847 | |
| 2.10 | -0.30 | -12.5% | 2.10 | 2.10 | 2.10 | 1,200 | |
| 2.40 | -0.10 | -4.0% | 2.40 | 2.40 | 2.40 | 1,900 | |
| 2.50 | +0.19 | +8.2% | 2.20 | 2.50 | 2.20 | 8,100 | |
| 2.31 | -0.28 | -10.8% | 2.50 | 2.54 | 2.31 | 20,421 | |
| 2.59 | +0.21 | +8.8% | 2.29 | 2.59 | 2.29 | 5,050 | |
| 2.38 | -0.03 | -1.2% | 2.49 | 2.49 | 2.38 | 10,100 | |
| 2.41 | 0.00 | 0.0% | 2.60 | 2.60 | 2.41 | 152 | |
| 2.41 | -0.23 | -8.7% | 2.42 | 2.42 | 2.41 | 12,000 | |
| 2.64 | -0.01 | -0.4% | 2.37 | 2.64 | 2.36 | 804 | |
| 2.65 | -0.11 | -4.0% | 2.65 | 2.65 | 2.65 | 7 | |
| 2.76 | 0.00 | 0.0% | 2.76 | 2.76 | 2.76 | 0 | |
| 2.76 | -0.04 | -1.4% | 2.76 | 2.76 | 2.76 | 200 | |
| 2.80 | 0.00 | 0.0% | 2.80 | 2.80 | 2.80 | 0 | |
| 2.80 | 0.00 | 0.0% | 2.80 | 2.80 | 2.80 | 100 | |
| 2.80 | +0.20 | +7.7% | 2.80 | 2.80 | 2.80 | 100 | |
| 2.60 | 0.00 | 0.0% | 2.65 | 2.65 | 2.47 | 3,687 | |
| 2.60 | -0.13 | -4.8% | 2.52 | 2.60 | 2.52 | 287 | |
| 2.73 | -0.01 | -0.4% | 2.75 | 2.75 | 2.73 | 590 | |
| 2.74 | +0.09 | +3.4% | 2.74 | 2.74 | 2.74 | 100 | |
| 2.65 | -0.14 | -5.0% | 2.52 | 2.80 | 2.52 | 20,553 | |
| 2.79 | 0.00 | 0.0% | 2.79 | 2.79 | 2.79 | 1,764 | |
| 2.79 | 0.00 | 0.0% | 2.52 | 2.79 | 2.52 | 1,764 | |
| 2.79 | -0.01 | -0.4% | 2.50 | 2.79 | 2.50 | 1,509 | |
| 2.80 | 0.00 | 0.0% | 2.80 | 2.80 | 2.80 | 4 | |
| 2.80 | +0.01 | +0.4% | 2.80 | 2.80 | 2.80 | 4 | |
| 2.79 | +0.09 | +3.3% | 2.80 | 2.80 | 2.55 | 6,908 | |
| 2.70 | -0.09 | -3.2% | 2.50 | 2.70 | 2.50 | 1,700 | |
| 2.79 | +0.04 | +1.5% | 2.80 | 2.80 | 2.79 | 1,680 | |
| 2.75 | -0.03 | -1.1% | 2.50 | 2.77 | 2.50 | 3,942 | |
| 2.78 | 0.00 | 0.0% | 2.78 | 2.78 | 2.78 | 1,372 | |
| 2.78 | -0.01 | -0.4% | 2.60 | 2.78 | 2.60 | 1,372 | |
| 2.79 | 0.00 | 0.0% | 2.79 | 2.79 | 2.79 | 4,904 | |
| 2.79 | +0.04 | +1.5% | 2.66 | 2.79 | 2.65 | 4,904 | |
| 2.75 | 0.00 | 0.0% | 2.75 | 2.75 | 2.75 | 7,082 | |
| 2.75 | +0.16 | +6.2% | 2.78 | 2.78 | 2.33 | 7,082 | |
| 2.59 | -0.19 | -6.8% | 2.78 | 2.79 | 2.59 | 10,552 | |
| 2.78 | -0.01 | -0.4% | 2.79 | 2.79 | 2.52 | 4,900 | |
| 2.79 | +0.10 | +3.7% | 2.55 | 2.79 | 2.50 | 5,659 | |
| 2.69 | -0.01 | -0.4% | 2.65 | 2.80 | 2.52 | 80,765 | |
| 2.70 | -0.10 | -3.6% | 2.80 | 2.80 | 2.55 | 30,929 | |
| 2.80 | -0.06 | -2.1% | 2.58 | 2.80 | 2.58 | 29,349 | |
| 2.86 | +0.06 | +2.1% | 2.85 | 2.87 | 2.84 | 1,752 | |
| 2.80 | -0.07 | -2.4% | 2.89 | 2.89 | 2.80 | 12,421 | |
| 2.87 | -0.17 | -5.6% | 2.89 | 2.90 | 2.80 | 36,329 | |
| 3.04 | +0.04 | +1.3% | 2.93 | 3.18 | 2.93 | 2,902 |
- Ticker
- Oslo:ABS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Oslo
- Currency
- NOK
What changed lately
Latest news release · Aug 27, 2026
Arctic Bioscience - Strong revenue growth and new data on HRO350 complementing the HeROPA trial results
Latest deck · Nov 11, 2026
Q3 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Arctic Bioscience - Strong revenue growth and new data on HRO350 complementing the HeROPA trial results
Aug 27, 2026
Closed 2.70 (-3.6%) on Aug 27, 2026
Arctic Bioscience presents HeROPA data at EADV in Athens
May 8, 2026
Closed 3.44 (+4.6%) on May 8, 2026
Arctic Bioscience AS: Consolidated 2025 Annual Report
May 7, 2026
Closed 3.29 (0.0%) on May 7, 2026
Arctic Bioscience - Annual report 2025
May 7, 2026
Closed 3.29 (0.0%) on May 7, 2026
Presentation of Q1-2026 update
Apr 30, 2026
Closed 3.30 (-4.3%) on Apr 30, 2026
Arctic Bioscience - 78% growth in Nutra revenues
Apr 30, 2026
Closed 3.30 (-4.3%) on Apr 30, 2026
Arctic Bioscience - Invitation to presentation of Q1 2026 operational update
Apr 24, 2026
Closed 3.39 (-1.7%) on Apr 24, 2026
Arctic Bioscience - Primary insiders who have provided bank guarantee
Apr 1, 2026
Closed 3.30 (0.0%) on Apr 1, 2026
Arctic Bioscience - New long-term financing
Apr 1, 2026
Closed 3.30 (0.0%) on Apr 1, 2026
Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells
Mar 19, 2026
Closed 3.10 (-8.3%) on Mar 19, 2026
Arctic Bioscience AS on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 19 in all · newest Aug 27, 2026 · oldest 2025
- Decks
- 6 decks · latest Nov 11, 2026
Where Arctic Bioscience AS is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Oslo:ABS · Home listing · This page | Oslo | Norway | NOK |
| Frankfurt:9TD | Frankfurt | Germany | EUR |
| Stuttgart:9TD | Stuttgart | Germany | EUR |
Valuation
EV/sales 2.8× against a median of 6.2×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 111.0M NOK
- P/E
- Loss
- EV/sales
- 2.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- 27.5%
- Operating margin
- −83.4%
- Net margin
- −102.3%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Ascelia Pharma AB · OMXSTO:ACE | US$7.30M | US$3.63M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| AEON Biopharma, Inc. · AMEX:AEON | US$7.27M | −US$4.15M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.04 |
| Pila Pharma AB · OMXSTO:PILA | US$7.01M | US$6.70M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | n/a |
| Cadrenal Therapeutics, Inc. · NASDAQ:CVKD | US$7.01M | US$3.95M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.60 |
| Ensysce Biosciences, Inc. · NASDAQ:ENSC | US$7.00M | −US$22.51M | n/a | −3.6× | n/a | 0.3× | n/a | 0.0× | 1.28 |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Curanex Pharmaceuticals Inc · NASDAQ:CURX | US$6.92M | US$5.88M | n/a | n/a | n/a | 2.7× | n/a | 0.2× | 0.84 |
| Cambium Bio Ltd · ASX:CMB | US$6.82M | US$6.18M | n/a | 14.6× | n/a | 4.3× | −638.4% | 0.1× | n/a |
| MetaVia Inc. · NASDAQ:MTVA | US$6.81M | −US$1.97M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 1.22 |
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| Median of the others | US$7.00M | US$3.79M | 6.2× | 2.8× | −638.4% | 0.0× | 1.22 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.00 NOK · Analysts' mean
- EPS, year to Dec 2026
- -0.89 · 1 analyst
- Revenue, year to Dec 2026
- 58M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Christer Valderhaug | CEO |
| Jone R. Slinning | CFO |
| Per Christian Sæbø | COO |
| Steffen Eidal | SVP Sales and Marketing |
| Yuming Feng | EVP Global Business Development |
| Daniele Mancinelli | CTO |
| Hogne Hallaråker | CSO/ Founder |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 32 slides | Nov 11, 2026 |
| H1 2026 Earnings Presentation | Earnings | 29 slides | Aug 27, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 29 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 26, 2026 |
| Q4 2023 Earnings Presentation | Earnings | 30 slides | Mar 1, 2024 |
| Investor Presentation (March 2021) | Investor deck | 24 slides | March 2021 |
Financials
Annual, in NOK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.1M | 43.5M | 33.8M | 34.3M | 21.5M | 20.5M | 30.0M | 24.8M |
| Cost of revenue | 29.1M | 31.6M | 24.0M | 22.6M | 16.4M | 15.2M | 17.8M | 15.9M |
| Gross profit | 11.0M | 11.9M | 9.78M | 11.6M | 5.16M | 5.31M | 12.2M | 8.95M |
| Research and development | 2.26M | 2.59M | 111.1K | 197.0K | ||||
| Operating income | -33.4M | -47.8M | -48.6M | -37.4M | 40.6M | -21.7M | -3.08M | -1.15M |
| Depreciation and amortization | 5.12M | 5.15M | 5.38M | 3.73M | 2.52M | 1.19M | 1.08M | 526.5K |
| EBITDA | -28.3M | -42.6M | -43.2M | -33.7M | 43.1M | -20.5M | -2.00M | -623.2K |
| Interest expense | 9.09M | 3.15M | 992.6K | 4.22K | 2.12M | 2.12M | 582.9K | 575.4K |
| Income before tax | -41.0M | -47.9M | -45.5M | -34.0M | -42.6M | -22.6M | -3.99M | -1.71M |
| Income tax | 3.37M | -82.8M | 561.2K | -437.3K | -40.6K | |||
| Net income | -41.0M | -47.9M | -45.5M | -34.0M | -42.6M | -22.6M | -3.99M | -1.71M |
| Earnings per share, basic | -1.52 | -1.88 | -1.79 | -1.40 | -1.75 | -0.93 | -0.16 | -0.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 258.4K | 2.16M | 79.6M | 144.2M | 227.4M | 12.6M | 23.4M | 368.8K |
| Receivables | 10.2M | 25.6M | 20.8M | 18.7M | 11.0M | 13.8M | 12.3M | 6.00M |
| Inventory | 29.6M | 29.0M | 32.8M | 35.5M | 28.5M | 26.2M | 17.5M | 15.9M |
| Current assets | 49.3M | 57.9M | 133.2M | 198.3M | 266.9M | 52.6M | 54.1M | 24.0M |
| Property, plant and equipment | 22.3M | 16.0M | 6.36M | 3.14M | ||||
| Goodwill | 1.34M | 1.93M | 2.53M | |||||
| Total assets | 284.7M | 279.7M | 300.3M | 327.7M | 341.5M | 93.2M | 82.5M | 45.4M |
| Accounts payable | 26.0M | 19.0M | 18.4M | 18.3M | 8.36M | 9.93M | 6.47M | 5.86M |
| Current liabilities | 83.0M | 67.5M | 39.6M | 40.4M | 20.9M | 22.7M | 11.4M | 15.3M |
| Long-term debt | 27.4M | 0 | 2.05M | 0 | 0 | 6.58M | 7.16M | 8.24M |
| Total debt | 32.9M | 2.05M | 1.10M | 4.18K | 8.46M | 7.16M | 12.1M | |
| Total liabilities | 111.2M | 69.0M | 41.7M | 40.4M | 20.9M | 29.3M | 18.6M | 23.5M |
| Shareholders' equity | 173.5M | 210.7M | 258.6M | 287.3M | 320.6M | 63.9M | 63.9M | 21.9M |
| Shares outstanding | 27.0M | 25.4M | 25.4M | 24.4M | 24.3M | 24.3M | 24.3M | 24.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -22.7M | -45.4M | -40.3M | -25.4M | -39.5M | -21.9M | 2.16M | |
| Capital spending | -22.7M | -50.8M | -45.3M | -58.6M | -36.5M | -13.4M | -13.4M | 0 |
| Free cash flow | -45.4M | -96.2M | -85.6M | -84.0M | -76.0M | -35.3M | 2.16M | |
| Cash from investing | -50.6M | -43.1M | -58.6M | -36.5M | -13.4M | -13.4M | ||
| Cash from financing | 19.7M | 18.8M | 750.0K | 290.8M | 23.9M | 23.9M | ||
| Change in cash | -1.99M | -76.3M | -64.5M | -83.2M | 214.8M | -11.4M | 23.2M |
Cap table
Built by 6ix from Arctic Bioscience AS’ releases
- Common shares
- 26,956,256
- Fully diluted
- 26,956,256
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 26,956,256 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 26,956,256 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christer L. Valderhaug | CEO · Since at least Aug 27, 2026 |
| Daniele Mancinelli | CTO · Since at least May 7, 2026 |
| Hogne Hallaråker | CSO/ Founder · Since at least May 7, 2026 |
| Jan Endre Vartdal | May 7, 2026 – Aug 27, 2026 · Past |
| Jone R. Slinning | CFO · Since at least Aug 27, 2026 |
| Per Christian Sæbø | COO · Since at least May 7, 2026 |
| Steffen Eidal | SVP Sales and Marketing · Since at least Nov 5, 2026 |
| Yuming Feng | EVP Global Business Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Arctic Bioscience AS.